Meet Dr. Steve Rose
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases.
ARVO Update: Powerful Protein Positioned Well for Human Study
May 10, 2012 03:43 pm - Posted by Steve R.
Dr. José Sahel
If you or someone you’re close to has a retinal degenerative disease, you should know about the vision-saving promise of a protein called Rod-derived Cone Viability Factor (RdCVF). It was discovered by Foundation-funded clinician-researchers Drs. José Sahel and Thierry Léveillard, of Institut de la Vision in Paris. In fact, they won the Foundation’s Board of Director’s Award in 2005 for the finding. It was a monumental effort, namely because they screened thousands of proteins to come up with the gem.
ARVO Update: News on Gene Therapy Clinical Trials for RP and Choroideremia
May 08, 2012 02:11 pm - Posted by Steve R.
Dr. Robert MacLaren
I was very excited to learn here at ARVO that two early-stage gene therapy clinical trials – one for choroideremia taking place in the U.K., the other for autosomal recessive retinitis pigmentosa (arRP) caused by MERTK mutations underway in Saudi Arabia – are proceeding well thus far. It is important to keep in mind that safety is the primary focus in these Phase I studies.
Read More
ARVO Poster: Nanoparticle Treatment Slows Vision Loss in Mice
May 07, 2012 03:28 pm - Posted by Steve R.
The Sunday morning poster session at ARVO included a Foundation-funded research effort from Oklahoma University (OU) in which Dr. Lily Wong and her colleagues used a nanoceria treatment to slow retinal degeneration in a mouse model of autosomal dominant retinitis pigmentosa (adRP).
Join Me (and 11,000 Other Eye Specialists) in Fort Lauderdale
May 05, 2012 12:00 pm - Posted by Steve R.
I invite you to join me, this coming week, in sunny Fort Lauderdale, Florida – not for spring break, but for something even better. As is always the case this time of year, the Association for Research in Vision and Ophthalmology (ARVO) will host its international conference, providing thousands of eye professionals with the latest information on retinal research and technologies.
The FDA’s Indispensible Role (a guest blog from Dr. Patricia Zilliox)
May 03, 2012 10:07 am - Posted by Patricia Z
To get a sight-saving treatment or therapy to the commercial market in the United States, you need three basic things: 1) scientists to discover and develop it; 2) money to support the research; and 3) Food and Drug Administration (FDA) marketing approval. While it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.